Gain Therapeutics, Inc.

Ownership Transactions Reported by 12 Insiders

Symbol
GANX on Nasdaq
Industry
Pharmaceutical Preparations
Location
4800 Hampden Lane, Suite 200, Bethesda, MD

Insiders trading volume in the past year

Gain Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Eric Richman Director $1.17M Jul 1, 2024
Khalid Islam Executive Chairman, Director $930K +$49.9K +5.68% Aug 9, 2024
Charles Evan Ballantyne Chief Financial Officer $125K Apr 10, 2023
Jeffrey Scott Riley Director $116K +$116K Jun 24, 2024
Matthias Alder Chief Executive Officer, Director $110K Mar 26, 2024
Salvatore Calabrese Chief Financial Officer $62.5K Mar 23, 2023
Gene Mack CFO and Interim CEO $14.5K +$14.5K Aug 9, 2024
Dov A. Goldstein Director Jun 24, 2024
Gianluca Fuggetta Principal Accounting and Financial Officer Mar 21, 2024
Hans Peter Hasler Director Jun 24, 2024
Gwen A. Melincoff Director Jun 24, 2024
Claude Nicaise Director Jun 24, 2024

Recent Insider Transactions by Companies or Individuals for Gain Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.